HG-120: CASE SERIES OF THREE PEDIATRIC BRAIN TUMOR PATIENTS TREATED WITH TUMOR-TREATING FIELDS

BACKGROUND: High-grade gliomas affect both children and adults and have similarly devastating outcomes, with few effective treatment options Optune is a device fitted to the scalp that applies low-intensity alternating electric fields (tumor-treating fields or TTF) continuously via electrodes. TTF showed non-inferiority to physician choice chemotherapy for recurrent glioblastoma (GBM) in adults and prolonged progression-free survival (PFS) and OS in adults with primary GBM in combination with temozolomide versus temozolomide alone. Little is known about the use of TTF in pediatric brain tumors. METHODS: We treated three pediatric brain tumor patients with TTF on a compassionate use basis. RESULTS: Patient 1 was a 21 yo male with a remote history of hematopoietic stem cell transplant with total body irradiation for Philadelphia-positive acute lymphoplastic leukemia, diagnosed with bifrontal anaplastic oligodendroglioma. TTF and bevacizumab were started at second recurrence. PFS was one month and OS 11 months. Patient 2 was a 16 yo male who started TTF, bevacizumab, CCNU, and radiosurgery at second recurrence of cortical epithelioid GBM. PFS was three months and OS eight months. Patient 3 was a 10 yo male who received TTF and bevacizumab as primary maintenance therapy for gliomatosis cerebri. He had six months PFS and seven months OS. No patient reported adverse events related to TTF therapy. CONCLUSIONS: TTF was well tolerated in three pediatric brain tumor patients. OS for two patients with second recurrences of aggressive tumors, and PFS for one patient with gliomatosis cerebri, were longer than expected. A pediatric clinical trial is warranted.